Apollomics Inc. develops clinical-stage oncology therapies for difficult-to-treat and treatment-resistant cancers. Company news centers on vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer and other tumors with c-Met alterations, along with broader pipeline work in targeted therapy and immuno-oncology.
Recurring updates also cover financial results, clinical-development spending, development and commercialization arrangements, bridge and private financings, Nasdaq listing compliance, board and committee changes, litigation resolution, and operating-continuity matters tied to the company’s biotechnology development model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.